LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.16 -1.69

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.16

Максимум

1.2

Ключови измерители
By Trading Economics
Приходи	3.5M -20M
EPS	-0.32
Служители	49
EBITDA	6.8M -22M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+130.17% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	6.7K 74M
Предишно отваряне	2.85
Предишно затваряне	1.16

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.06.2026 г., 21:51 ч. UTC

Значими двигатели на пазара

Merlin Shares Rally After Defense Department's Design Review Wraps

4.06.2026 г., 23:46 ч. UTC

Пазарно говорене

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4.06.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4.06.2026 г., 23:42 ч. UTC

Придобивния, сливания и поглъщания

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4.06.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

Energy Resources of Australia to Enter Trading Halt

4.06.2026 г., 23:34 ч. UTC

Пазарно говорене

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.06.2026 г., 23:08 ч. UTC

Пазарно говорене

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4.06.2026 г., 22:41 ч. UTC

Пазарно говорене

Australia Shares Set to Rise at the Open -- Market Talk

4.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.06.2026 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4.06.2026 г., 20:16 ч. UTC

Пазарно говорене

Mexican Demand Indicators Show Signs of Life -- Market Talk

4.06.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4.06.2026 г., 19:46 ч. UTC

Пазарно говорене

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4.06.2026 г., 19:38 ч. UTC

Пазарно говорене

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4.06.2026 г., 19:30 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4.06.2026 г., 18:47 ч. UTC

Придобивния, сливания и поглъщания

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4.06.2026 г., 18:38 ч. UTC

Печалби

Money Quote: Tech Weakness in Context -- WSJ

4.06.2026 г., 18:24 ч. UTC

Печалби

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4.06.2026 г., 17:09 ч. UTC

Пазарно говорене

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4.06.2026 г., 16:58 ч. UTC

Печалби

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4.06.2026 г., 16:46 ч. UTC

Пазарно говорене

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4.06.2026 г., 16:38 ч. UTC

Печалби

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

4.06.2026 г., 16:13 ч. UTC

Пазарно говорене

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4.06.2026 г., 16:11 ч. UTC

Пазарно говорене

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4.06.2026 г., 15:56 ч. UTC

Пазарно говорене

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

130.17% нагоре

12-месечна прогноза

Среден 2.67 USD 130.17%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.